Allogene Therapeutics (ALLO) Non Operating Income (2018 - 2026)
Allogene Therapeutics (ALLO) posted Non Operating Income of $3.5 million for Q1 2026, down 3.03% sequentially from $3.6 million in Q4 2025, and down 36.15% YoY from $5.5 million in Q1 2025.
Allogene Therapeutics (ALLO) Non Operating Income (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Non Operating Income for 9 years, with the latest figure at $3.5 million in Q1 2026.
- Quarterly Non Operating Income fell 36.15% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.5 million (down 3.23% YoY) and the FY2025 annual result came in at $18.4 million, up 14.81% from the prior year.
- Non Operating Income slipped to $3.5 million in Q1 2026 per ALLO's latest filing, from $3.6 million in the prior quarter.
- Over five years, Non Operating Income peaked at $5.9 million in Q2 2025 and troughed at -$3.7 million in Q2 2022.
- A 5-year average of $2.1 million and a median of $3.5 million in 2026 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 4050.54% in 2022, then soared 673.06% in 2024.
- Over 5 years, Non Operating Income stood at -$880000.0 in 2022, then gained by 23.98% to -$669000.0 in 2023, then jumped by 248.58% to $994000.0 in 2024, then jumped by 261.57% to $3.6 million in 2025, then retreated by 3.03% to $3.5 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $3.5 million, $3.6 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 4.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.24 Mn |
| Mar 31, 2026 | 3.49 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 5.88 Mn |
| Mar 31, 2025 | 5.46 Mn |
| Dec 31, 2024 | 994,000.00 |
| Sep 30, 2024 | 5.48 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Mar 31, 2024 | 4.50 Mn |
| Dec 31, 2023 | -669,000.00 |
| Sep 30, 2023 | 709,000.00 |
| Jun 30, 2023 | 3.78 Mn |
| Mar 31, 2023 | -876,000.00 |
| Dec 31, 2022 | -880,000.00 |
| Sep 30, 2022 | -1.73 Mn |
| Jun 30, 2022 | -3.67 Mn |
| Mar 31, 2022 | 1.41 Mn |
| Dec 31, 2021 | -1.62 Mn |
| Sep 30, 2021 | -516,000.00 |